Accelerated (malignant) hypertension: A study of 121 cases between 1974 and 1996

Journal of Nephrology

Volumn 10, Issue 4, 1997, Pages 207-215

  Scarpelli, Paolo T ^a   Livi, Riccardo ^a   Caselli, Gian Marco ^a   Di Maria, Lorenzo ^a   Teghini, Laila ^a   Montemurro, Vincenzo ^a   Toti, Gabriele ^a   Becucci, Aureliano ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Accelerated hypertension; Blood pressure self measurement; Hypotensive treatment; Malignant hypertension; Renal function; Retinopathy; Survival rate

Indexed keywords

BLOOD PRESSURE MEASUREMENT; CHRONIC DIARRHEA; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DIFFERENTIAL DIAGNOSIS; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; RECURRENT DISEASE; RETINOPATHY; SURVIVAL RATE; TREATMENT PLANNING;

ADMINISTRATION, ORAL; ADULT; BLOOD PRESSURE; CLONIDINE; CREATININE; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; NIFEDIPINE; RETINAL DISEASES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030818027     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Harrington M, Kincaid-Smith P, McMichael J. Results of treatment in malignant hypertension. A seven year experience in 94 cases. Brit Med J 1959; 2: 969-80.
2. Pohl JEF, Thurston H, Swales JD. Hypertension with renal impairment: influence of intensive therapy. Quart J Med 1974; 43: 569-81.
3. Gudbrandsson T, Hansson L, Herlitz H, Andren L. Malignant hypertension - improving prognosis in a rare disease. Acta Med Scand 1979; 200: 495-9.
4. Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1939; 197: 332-43.
5. Fabiani J-N, Carpentier A. La méthode actuarielle pour l'analyse statistique des résultats cliniques et experimentaux. Nouv Presse Med 1977; 6: 357-61.
6. Lee TH, Alderman MH. Malignant hypertension. Declining mortality rate in New York City, 1958 to 1974. New York State J Med 1978; 78: 1389-91.
7. Lip GYH, Beevers M, Beevers G. The failure of malignant hypertension to decline: a survey of 24 years' experience in a multiracial population in England. J Hypertens 1994; 12: 1297-305.
8. Scarpelli PT, Brancato R, Menchini U, Santoro P, Lamanna S. The close interrelationship between increased vascular retinal permeability and blood pressure level. Evidence from retinal fluoroangiography. Ophtalmologica 1977; 175: 309-20.
9. Tso MOM, Jampol LM. Hypertensive retinopathy, choroidopathy and optic neuropathy of hypertensive ocular disease. A clinical and pathophysiologic approach to classification. In: Laragh JH, Brenner BM, eds. Hypertension. Pathophysiology, diagnosis and management. New York: Raven Press, 1990; I: 433-65.
10. Hood B, Orndahl G, Bjork S. Survival and mortality in malignant (grade IV) and grade III hypertension. Trends in consecutive, actively, treated groups. Acta Med Scand 1970; 187: 291-302.
11. Ahmed MEK, Walker JM, Beevers M. Lack of difference between malignant and accelerated hypertension. Brit Med J 1986; 292: 235-7.
12. McGregor E, Isles CG, Jay JI, Lever AF, Murray GD. Retinal changes in malignant hypertension. Brit Med J 1986; 292: 233-7.
13. Beilin LJ, Goldby FS. High arterial pressure versus humoral factors in the pathogenesis of the vascular lesions of malignant hypertension. Clin Sci Mol Med 1977; 52: 111-3.
14. Mohring J. The case for humoral factors as well as pressure. Clin Sci Mol Med 1977; 52: 113-7.
15. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18-32.
16. Hayreh SS, Servais GE, Virdi PS, Marcus ML, Rojas P, Woolson RF. Fundus lesions in malignant hypertension. III. Arterial blood pressure, biochemical, and fundus changes. Opthalmology 1986; 93: 45-59.
17. Hayreh SS, Servais GE, Virdi PS. Fundus lesions in malignant hypertension IV. Focal retinal periarteriolar transudates. Ophthalmology 1986; 93: 60-73.
18. Hayreh SS, Servais GE, Virdi PS. Fundus lesions in malignant hypertension. V. Hypertensive optic neuropathy. Ophtalmology 1986; 93: 74-87.
19. Hayreh SS, Servais GE, Virdi PS. Fundus lesions in malignant hypertension. VI. Hypertensive choroidopathy. Ophtalmology 1986; 93: 1383-400.
20. Luke RG, Curtis JS. Nephrosclerosis. In: Schrier RW, Gottschalck CW, eds; Disease of the kidney. Vol. II. Boston/Toronto/London: Little, Brown Co, 1993; 1433-50.
21. Moyer JH, Heider C, Pevey K, Ford RV. The effect of treatment on the vascular deterioration associated with hypertension, with particular emphasis on renal function. Am J Med 1958; 24: 179-92.
22. Mroczkec WJ, Davidov M, Gavrilovich L, Finnerty FA Jr. The value of aggressive therapy in the hypertensive patient with azotemia. Circulation 1969; 40: 893-904.
23. Volhard F. On pathogenesis of red (essential) arterial hypertension and of malignant nephrosclerosis (Festschift for Thomas Addis). Stanford Med Bull 1948; 6: 13 (745).
24. Laragh GH, Baer L, Brunner HR, Buhler FR, Scaley JE, Vaughan ED Jr. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52: 633-52.
25. Wilson C, Byrom FB; The vicious circle in chronic Bright's disease: experimental evidence from the hypertensive rat. Quart J Med N S 1941; 10: 65-93.
26. Lip GYH, Beevers M, Beevers DG. Complications and survival of 315 patients with malignant-phase hypertension. J Hypertens 1995; 13: 915-24.